Matrix metalloproteinases in cancer metastasis: An unsolved mystery

Role of Proteases in Cellular Dysfunction

Volumn , Issue , 2014, Pages 187-212

  Mukherjee, Shravanti ^a   Manna, Argha ^a   Mazumdar, Minakshi ^a   Das, Tanya ^a  

^a BOSE INSTITUTE   (India)

Author keywords

Cancer stem cell; Epithelial to mesenchymal transition; Invasion; Matrix metalloproteinases; Metastasis; Migration; Tissue inhibitors of metalloproteinases

Indexed keywords

EID: 84978814319     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-9099-9_10     Document Type: Chapter

References (124)

1. Renee T (2005) Cancer Surpasses Heart Disease as Leading Cause of Death for All But the Very Elderly. J Natl Cancer Inst 97: 330-331
2. Joyce JA, Jeffrey W (2009) Pollard Microenvironmental regulation of metastasis. Nat Rev Cancer 9: 239-252
3. Saha B, Adhikary A, Ray P et al (2012) Restoration of tumor suppressor p53 by differentially regulating pro and anti p53 networks in HPV 18 infected cervical cancer cells. Oncogene 31: 178-186
4. Mazumdar M, Adhikary A, Chakraborty S et al (2013) Targeting RET to induce medullary thyroid cancer cell apoptosis in antagonistic interplay between PI3K/Akt and P38MAPK/ caspase 8 pathways. Apoptosis 18: 587-604
5. Sen GS, Mohanty S, Bhattacharyya S et al (2011) Curcumin enhances the efficacy of chemotherapy by tailoring p65NFkB-p300 cross-talk in favor of p53-p300 in breast cancer. J Biol Chem 286: 42232-42247
6. Das T, Sa G, Saha B et al (2010) Multifocal signal modulation therapy of cancer: Ancient weapon, modern targets. Mol Cell Biochem 336: 85-95
7. Lahiry L, Saha B, Chakraborty J et al (2010) Theaflavin targets Fas/Caspase 8 and Akt/pBad pathways to induce apoptosis in p53 mutated human breast cancer cells. Carcinogenesis 31: 259-268
8. Lahiry L, Saha B, Chakraborty J et al (2008) Contribution of p53 mediated Bax transactivation in theaflavin induced mammary epithelial carcinoma cell apoptosis. Apoptosis 13: 771-781
9. nd edition, New York: McGraw-Hill, Medical Pub, 3-7, 2002
10. Katherine N, Weilbaecher T A, McCauley K. (2011) "Cancer to Bone" A fatal attraction. Nat Rev Cancer 11: 411-425
11. Frantz C, Stewart KM, Weaver VM (2010) The extracellular matrix at a glance. J Cell Sci 123:4195-4200
12. Stetler-Stevenson WG, Aznavoorian S, Liotta LA (1993) Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 9: 541-573
13. Wolf K, Wu YI, Liu Y et al (2007) Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat Cell Biol 9: 893-904
14. Kenneth A Iczkowski (2011) Cell adhesion molecule CD44: its functional roles in prostate cancer Am J Transl Res 3: 1-7
15. Rundhaug JE (2003) Matrix Metalloproteinases, Angiogenesis, and Cancer. Clin Cancer Res 9 (2): 551-554
16. Cavallo-Medved D, Rudy D, Blum G et al (2009) Live-cell imaging demonstrates extracellular matrix degradation in association with active cathepsin B in caveolae of endothelial cells during tube formation. Exp Cell Res 315: 1234-1246
17. Chua KN, Poon KL, Lim J et al (2011) Target cell movement in tumor and cardiovascular diseases based on the epithelial-mesenchymal transition concept. Adv Drug Deliv Rev 63: 558-567
18. Kimura YN, Watari K, Fotovati A, et al (2007) Inflammatory stimuli from macrophages and cancer cells synergistically promote tumor growth and angiogenesis. Cancer Sci 98: 2009-2018
19. Albert R. Davalos, Jean-Philippe Coppe, Judith Campisi (2010) Senescent cells as a source of inflammatory factors for tumor progression. Cancer Meta Rev 29: 273-283
20. Ram M, Sherer Y, Shoenfeld Y (2006) Matrix metalloproteinase-9 and autoimmune diseases. J Clin Immunol 26: 299-307
21. Adhikary A, Mohanty S, Lahiry L et al (2009) Theaflavins retards human breast cancer cell migration by inhibiting NF£B via p53-ROS crosstalk. FEBS L 584: 7-14
22. Sewon N, Jung Joon J, Jung M et al (2012) Body fluid MMP-2 as a putative biomarker in metastatic breast cancer. Onco Lett 3: 699-703
23. Opdenakker G, Philippe E. Van den Steen et al (2001) Gelatinase B functions as regulator and effector in leukocyte biology. J Leuko Biol 69: 851-859
24. Vu TH, Werb Z (2000) Matrix metalloproteinases: effectors of development and normal physiology. Genes & Dev 14: 2123-2133
25. Audic Y, Hartley RS (2004) Post-transcriptional regulation in cancer. Biol Cell 96: 479-498
26. Lochter A, Srebrow A, Sympson CJ et al (1997) Misregulation of Stromelysin-1 Expression in Mouse Mammary Tumor Cells Accompanies Acquisition of Stromelysin-1-dependent Invasive Properties. J Biol Chem 272: 5007-5015
27. Wysocki AB, Staiano-Coico L, Giinnell F (1993) Wound Fluid from Chronic Leg Ulcers Contains Elevated Levels of Metalloproteinases MMP-2 and MMP-9. J Invest Dermatol 101: 64-68
28. Malemud CJ (2006) Matrix metalloproteinases (MMPs) in health and disease: an overview. Front in Biosc 11: 1696-1701
29. Fingleton B (2007) Matrix Metalloproteinases as Valid Clinical Targets. Curr Pharmac Des 13: 333-346
30. Gomis-Rüth FX (2003) Structural aspects of the metzincin clan of metalloendopeptidases. Mol Biotech 24:157-202
31. Gomis-Rüth FX (2009) Catalytic Domain Architecture of Metzincin Metalloproteases. J Biol Chem 284: 15353-15357
32. Overall CM, López-Otín C (2002) Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2: 657-672
33. Eisen A, Jeffrey J, Gross J (1968) Human skin collagenase. Isolation and mechanism of attack on the collagen molecule. Biochim Biophys Acta 151: 637-645
34. Fontana V, Coll TA, Sobarzo CM et al (2012) Matrix metalloproteinase expression and activity in trophoblast-decidual tissues at organogenesis in CF-1 mouse. J Mol Histol 43(5): 487-496
35. Parks WC, Wilson CL, López-Boado YS (2004) Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 4: 617-629
36. Fridman R (2006) Metalloproteinases and cancer. Cancer Metastasis Rev 25: 7-8
37. Van Wart H, Birkedal-Hansen H (1990) The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci USA 87: 5578-5582
38. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174
39. Pei D, Kang T, Qi H (2000) Cysteine array matrix metalloproteinase (CA-MMP)/MMP-23 is a type II transmembrane matrix metalloproteinase regulated by a single cleavage for both secretion and activation. J Biol Chem 275: 33988-33997
40. Morgunova E, Tuuttila A, Bergmann U et al (1999) Structure of Human Pro-Matrix Metalloproteinase-2: activation mechanism revealed. Sci 284: 1667-1670
41. Bode W (1995) A helping hand for collagenases: the haemopexin-like domain. Struct 3(6): 527-30
42. Kojima K, Ogawa H, Matsumoto I, Yoneda A (1998) Characterization of the ligand binding activities of vitronectin: interaction of vitronectin with lipids and identification of the binding domains for various ligands using recombinant domains. Biochem 37: 6351-6360
43. Massova I, Kotra LP, Fridman R, Mobashery S (1998) Matrix metalloproteinases: structures, evolution, and diversification. FASEB J 12: 1075-1095
44. Kojima S, Itoh Y, Matsumoto S (2000) Membrane-type 6 matrix metalloproteinase (MT6- MMP, MMP-25) is the second glycosyl-phosphatidyl inositol (GPI)-anchored MMP. FEBS Letter 480: 142-146
45. Monea S, Lehti K, Keski-Oja J, Mignatti P et al (2002) Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism. J Cell Physiol 192: 160-170
46. Park BC, Thapa D, Lee YS et al (2007)1-furan-2-yl-3-pyridin-2-yl-propenone inhibits the invasion and migration of HT1080 human fibrosarcoma cells through the inhibition of proMMP-2 activation and down regulation of MMP-9 and MT1-MMP. Eur J Pharmacol. 587: 193-197
47. Brooke C. Henderson, Suresh C. Tyagi (2006) Oxidative mechanism and homeostasis of proteinase/antiproteinase in congestive heart failure. J Mol and Cell Cardiol 41: 959-962
48. Fu X, Kassim SY, Parks WC (2003) Hypochlorous Acid Generated by Myeloperoxidase Modifies Adjacent Tryptophan and Glycine Residues in the Catalytic Domain of Matrix Metalloproteinase-7: An Oxidative: Mechanism for Restraining Proteolytic Activity during Inflammation. J Biol Chem 278: 28403-28409
49. Visse R, Nagase H (2003) Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases:Structure, Function, and Biochemistry. Circul Res 92: 827-839
50. Rupp PA, Visconti RP, Czirók A et al (2008) Matrix Metalloproteinase 2-Integrin avß3 Binding Is Required for Mesenchymal Cell Invasive Activity but Not Epithelial Locomotion: A Computational Time-Lapse Study. Mol Biol Cell 19: 5529-5540
51. Zarrabi K, Dufour A, Li J, Kuscu C et al (2011)Inhibition of matrix metalloproteinase 14 (MMP-14)-mediated cancer cell migration. J Biol Chem. 286: 33167-33177
52. Levental KR, Yu H, Kass L et al (2009) Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling. Cell: 891-906
53. Smith ML, Gourdon D, Little WC, Kubow KE, Eguiluz RA et al (2007) Force-Induced Unfolding of Fibronectin in the Extracellular Matrix of Living Cells. PLoS Biol 5: e268
54. Wirtz D, Konstantopoulos K, Searson PC (2011) The physics of cancer: the role of physical interactions and mechanical forces in metastasis. Nat Rev Cancer 11: 512-522
55. Würtz SØ, Schrohl AS, Sørensen NM (2005) Tissue inhibitor of metalloproteinases-1 in breast cancer. Endocr Relat Cancer 12: 215-227
56. Ogata Y, Itoh Y, Nagase H (1995) Steps Involved in Activation of the Pro-matrix Metalloproteinase 9 (Progelatinase B)-Tissue Inhibitor of Metalloproteinases-1 Complex by 4-Aminophenylmercuric Acetate and Proteinases. J Biol Chem 270: 18506-18511
57. Seo DW, Li H, Guedez L et al (2003) TIMP-2 Mediated Inhibition of Angiogenesis: An MMP-Independent Mechanism. Cell 114: 171-180
58. Basu R, Fan D, Kandalam V et al (2012) Loss of Timp3 leads to abdominal aortic aneurysm formation in response to angiotensin II. J Biol Chem 287: 44083-44096
59. Tummalapalli CM, Heath BJ, Tyagi SC (2001) Tissue inhibitor of metalloproteinase-4 instigates apoptosis in transformed cardiac fibroblasts. J Cell Biochem 80: 512-521
60. DeBerardinis RJ. (2012) Good neighbours in the tumour stroma reduce oxidative stress. Nat Cell Biol 14: 235-236
61. Mishra P, Banerjee D, Baruch AB (2011) Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy. J Leukoc Biol 89: 31-39
62. Bekes EM, Schweighofer B, Kupriyanova TA (2011) Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation. Am J Pathol 179: 1455-1470
63. Schmalfeldt B, Prechtel D, Härting K et al (2001) Increased Expression of Matrix Metalloproteinases (MMP)-2, MMP-9, and the Urokinase-Type Plasminogen Activator Is Associated with Progression from Benign to Advanced Ovarian Cancer. Clin Cancer Res 7: 2396-2404
64. Kuittinen O, Apaja-Sarkkinen M, Turpeenniemi-Hujanen T (2003) Gelatinases (MMP-2 and MMP-9), TIMP-1 expression and the extent of neovascularization in aggressive non-Hodgkin's lymphomas. Eur J Haematol 71: 91-109
65. Koshiba T, Hosotani R, Wada M (1998) Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma. Cancer 82: 642-650
66. Choi JY, Jang YS, Min SY (2011) Overexpression of MMP-9 and HIF-1A in Breast Cancer Cells under Hypoxic Conditions. J Breast Cancer 14: 88-95
67. Kedrin D, Gligorijevic B, Wyckoff J et al (2008) Intravital imaging of metastatic behavior through a mammary imaging window. Nat Meth 5: 1019-1021
68. Koop S, Khokha R, Schmidt EE et al (1994) Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res 54: 4791-4797
69. Royer C, Lu X (2011) Epithelial cell polarity: a major gatekeeper against cancer? Cell Death Differ 18:1470-1477
70. Vernon AE, LaBonne C et al (2004)Tumor Metastasis: A New Twist on EpithelialMesenchymal Transitions. Current Biol 14: 719-721
71. Brabletz T, Herrmann K, Jung A et al (2000)Expression of Nuclear ß-Catenin and c-myc Is Correlated with Tumor Size but Not with Proliferative Activity of Colorectal Adenomas. Am J Pathol 156: 865-870
72. Lynch CC, Vargo-Gogola T, Matrisian LM et al (2010) Cleavage of E-Cadherin by Matrix Metalloproteinase-7 Promotes Cellular Proliferation in Nontransformed Cell Lines via Activation of RhoA. J of Oncol 2010: 530745
73. Liu P, Yang J, Pei J, Pei D, Wilson MJ (2010) Regulation of MT1-MMP activity by ß-catenin in MDCK non-cancer and HT1080 cancer cells. J Cell Physiol 225: 810-821
74. Frittoli E, Palamidessi A, Disanza A (2012) Secretory and endo/exocytic trafficking in invadopodia formation: the MT1-MMP paradigm. Eur J Cell Biol 90(2-3): 108-114
75. Nascimento CF, Gama-De-Souza LN, Freitas VM (2010) Role of MMP9 on invadopodia formation in cells from adenoid cystic carcinoma. Study by laser scanning confocal microscopy. Microsc Res Tech 73: 99-108
76. Mizutani K, Kofuji K, Shirouzu K (2000) The significance of MMP-1 and MMP-2 in peritoneal disseminated metastasis of gastric cancer. Surg Today 30: 614-621
77. Yang EV, Sood AK, Chen M (2006) Norepinephrine Up-regulates the Expression of Vascular Endothelial Growth Factor, Matrix Metalloproteinase (MMP)-2, and MMP-9 in Nasopharyngeal Carcinoma Tumor Cells. Cancer Res 66: 10357-10364
78. Szabova L, Chrysovergis K, Yamada S (2008) MT1-MMP is required for efficient tumor dissemination in experimental metastatic disease. Oncogene 27: 3274-3281
79. Davies B, Miles DW, Happerfield LC (1993) Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 67: 1126-1131
80. DeClerck YA, Imren S (1994) Protease inhibitors: role and potential therapeutic use in human cancer. Eur J Cancer 30A: 2170-2180
81. Lu XQ, Levy M, Weinstein IB et al (1991) Immunological quantitation of levels of tissue inhibitor of metalloproteinase-1 in human colon cancer. Cancer Res 51: 6231-6235
82. L Guedez, W G Stetler-Stevenson, L Wolff et al (1998) In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest 102: 2002-2010
83. Zucker S, Lysik RM, Makk M et al (1992) Secretion of Gelatinases and Tissue Inhibitors of Metalloproteinases by Human Lung-Cancer Cell-Lines and Revertant Cell-Lines - Not an Invariant Correlation with Metastasis. Int J Cancer 52: 366-371
84. Parks WC (1999) Matrix metalloproteinases in repair. Wound Rep Regen 7: 423-432
85. Packard BZ, Artym VV, Komoriya A, Yamada KM (2009) Direct visualization of protease activity on cells migrating in three-dimensions. Matrix Biol 28: 3-10
86. Giannelli G, Pozzi A, Stetler-Stevenson WG et al (1999)Expression of matrix metalloprotease- 2-cleaved laminin-5 in breast remodeling stimulated by sex steroids. Am J Pathol 154: 1193-1201
87. Xu J, Rodriguez D, Petitclerc E et al (2001) Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol 154: 1069-1080
88. Okamoto I, Tsuiki H, Kenyon CL et al (2002) Proteolytic Cleavage of the CD44 Adhesion Molecule in Multiple Human Tumors. Am J Pathol 160: 441-447
89. st edition, Springer, 29-50, 2012
90. Paiva De CS, Yoon KC, Pangelinan BS (2009) Cleavage of functional IL-2 receptor alpha chain (CD25) from murine corneal and conjunctival epithelia by MMP-9. J Inflamm 6: 31-42
91. Becker C, Fantini MC, Neurath MF (2006) TGF-beta as a T cell regulator in colitis and colon cancer. Cytokine and growth factor reviews 17: 97-106
92. Kataoka H, Uchino H, Iwamura T (1999) Enhanced Tumor Growth and Invasiveness in Vivo by a Carboxyl-Terminal Fragment of a1-Proteinase Inhibitor Generated by Matrix Metalloproteinases. Am J Pathol 154: 457-468
93. Webster NL, Crowe SM (2006) Matrix metalloproteinases, their production by monocytes and macrophages and their potential role in HIV-related diseases. J Leukoc Biol 80: 1052-1066
94. Stephanie J. Mail G, Kurschat N, Drenckhan A (2012) Involvement of CXCR4 Chemokine Receptor in Metastastic HER2-Positive Esophageal Cancer. PLOS One 7: e47287
95. Davalos AR, Coppe JP, Campisi J et al (2010)Senescent cells as a source of inflammatory factors for tumor progression. Cancer Metast Rev 29: 273-283
96. Pengfei L, Weaver MV, Werb Z (2012) The extracellular matrix: A dynamic niche in cancer progression. J Cell Biol 196: 395-406
97. Huang Y, Song N, Ding Y et al (2009) Pulmonary vascular destabilization in the premetastatic phase facilitates lung metastasis. Cancer Res 69: 7529-7537
98. Song N, Sung H, Choi JY et al (2012) Preoperative serum levels of matrix metalloproteinase- 2 (MMP-2) and survival of breast cancer among Korean women. Cancer Epidemiol Biomarkers Prev 21(8):1371-1380
99. Demeter A, Sziller I, Csapo Z et al (2005) Molecular Prognostic Markers in Recurrent and in Non-recurrent Epithelial Ovarian Cancer. Antican Res 25: 2885-2890
100. Kuniyasu H, Lee ME, Douglas B et al (1999) Relative Expression of E-Cadherin and Type IV Collagenase Genes Predicts Disease Outcome in Patients with Resectable Pancreatic Carcinoma. Clin Cancer Res 5: 25-33
101. Yamamoto H, Itoh F, Shouhei I et al (2001) Expression of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Human Pancreatic Adenocarcinomas: Clinicopathologic and Prognostic Significance of Matrilysin Expression. J Clin Oncol 19: 1118-1127
102. Moser PL, Kieback DG, Hefler L et al (1999)Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2 and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage IB cervical cancer. Anticancer Res.19: 4391-4393
103. Inoue T, Yashiro M, Nishimura S et al (1999) Matrix metalloproteinase-1 expression is a prognostic factor for patients with advanced gastric cancer. Int J Mol Med 4: 73-80
104. Yoshizaki T, Maruyama Y, Sato H et al (2001) Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma. Int J Cancer 95: 44-50
105. Zeng ZS, Huang Y, Cohen AM et al (1996) Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol 14: 3133-3140
106. Gokaslan ZL, Chintala SK, York JE et al (1998) Expression and role of matrix metalloproteinases MMP-2 and MMP-9 in human spinal column tumours. Clin Exp Metastasis 16: 721-728
107. Gojhi K, Fujimoto N, Hara I (1998) Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int J Cancer 79: 96-101
108. Slaton JW, Inoue K, Perrotte P et al (2001) Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol 158: 735-743
109. Verline J, Regala RP, Tseng CI (2012)Matrix Metalloproteinase-10 Is Required for Lung Cancer Stem Cell Maintenance, Tumor Initiation and Metastatic Potential. PLoS one 7: e35040
110. Coussens LM, Fingleton B, Matrisian LM (2012) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Sci. 295: 2387-2392
111. Talbot DC, Brown P (1996) Experimental and clinical studies on the use of matrix metallo proteinases inhibitor for the treatment of cancer. Eur J Cancer 32A: 2528-2533
112. Nemunaitis J, Poole C, Primrose J et al (1998) Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: Selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res 4: 1101-1109
113. Sparano JA, Bernardo P, Stephenson P et al (2004)Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2 196. J Clin Oncol 22: 4683-4690
114. Miller KD, Saphner TJ, Waterhouse DM et al (2004)A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer. Clin Cancer Res 10: 1971-1975
115. Overall CM, Kleifeld O (2006) Tumour microenvironment-opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 6: 227-239
116. Montel V, Kleeman J, Agarwal D et al (2004) Altered metastatic behavior of human breast cancer cells after experimental manipulation of matrix metalloproteinase 8 gene expression. Cancer Res 64: 1687-1694
117. Gutierrez-Fernandez A, Fueyo A, Folgueras AR et al (2008) Matrix metalloproteinase-8 functions as a metastasis suppressor through modulation of tumor cell adhesion and invasion. Cancer Res 68: 2755-2763
118. Sternlicht MD, Lochter A, Sympson CJ et al (1999) The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis Cell 98: 137-146
119. Moy FJ, Chanda PK, Chen J et al (2002) Impact of mobility on structure-based drug design for the MMPs. J Am Chem Soc 124: 12658-12659
120. Jacobsen JA, Major Jourden JL, Miller MT et al (2010) To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition. Biochim Biophys Acta 1803: 72-94
121. Ikejiri M, Bernardo MM, Meroueh SO et al (2005) Design, synthesis, and evaluation of a mechanism-based inhibitor for gelatinase A. J Org Chem 70: 5709-5712
122. Sela-Passwell N, Rosenblum G, Shoham T, et al (2009) Structural and functional bases for allosteric control of MMP activities: Can it pave the path for selective inhibition? Biochim Biophys Acta 1803: 29-38
123. Williamson RA, Hutton M, Vogt G et al (2001) Tyrosine 36 plays a critical role in the interaction of the AB loop of tissue inhibitor of metalloproteinases-2 with matrix metalloproteinase-14. J Biol Chem 276: 32966-32970
124. Lee MH, Atkinson S, Rapti M et al (2009) The activity of a designer tissue inhibitor of metalloproteinases (TIMP)-1 against native membrane type 1 matrix metalloproteinase (MT1-MMP) in a cell-based environment. Cancer Lett 290: 114-122